Throughout my research career I have been fascinated by how differentiated cells are maintained in adult mammalian tissues and in how the regulatory processes are disturbed in cancer. As a cell biologist, I think of these problems in terms of the behavior of individual cells.

When I started my research career, a small number of immortalized cell lines that underwent differentiation in culture were available, and researchers had already put some effort into culturing primary cells from different tissues. These cultures were the main research tools available. The field changed completely with the advent of techniques for genetically modifying mice, and at present most researchers in the field use a combination of in vitro and in vivo approaches. We now have large numbers of markers of stem cells and differentiated cells and techniques for monitoring lineage relationships in adult tissues. In addition, many of the key regulatory pathways have been defined. Conceptually, the importance of stem cells, both in normal tissues and certain tumors, is well established.
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So, what does the future hold? I am optimistic that stem cell research will deliver real clinical benefits, both by providing better drugs to treat disease and by providing additional strategies to restore stem cell depletion. Cell biologists have a lot to contribute to this goal, as we are well placed to identify the external signals that control stem cell properties. Interactions between stem cells and their local environment (niche) involve cell adhesion, growth factor signaling, and other types of intercellular communication, all of which can be explored at the cellular level. However, for us to participate fully in achieving this goal, we must embrace research at the interface between the lab and the clinic.

In terms of emerging technologies, there are great opportunities for cell biologists to collaborate with bioengineers and biomaterials scientists to elucidate the stem cell niche. Advances in those technologies combined with sophisticated microscopical analysis will form the basis for better drug screens. To complement the in vitro studies, techniques for imaging cell behavior in living mice will only get better.

We will not have to spend so long labeling tissues with antibodies as this information becomes available as a Web-based tool. International efforts to knockout all genes in the mouse and make the mutant mouse lines available will put in vivo analysis within reach of more cell biologists. We will spend less time at the bench and more time analyzing the datasets we generate: we will need to acquire the skill sets of bioinformaticians, aided by freeware on the Web. I believe that data sharing on a large scale will be a refreshing change for cell biologists and it is one that I embrace enthusiastically.

What about cancer? The same technology that is used to probe normal tissue function will be applicable to the study of disease. Large amounts of genomic information are being obtained from individual tumors and from people with increased risk of developing cancer. Explaining what this means in terms of the behavior of tumor cells in the context of their host environment will be a major achievement for cell biologists. We will have to find the best cancer models to study, and at present opinions are heavily polarized between those who study defined populations of human tumor cells in immunocompromised mice and those who study tumors induced directly in mice.

In closing, I look back at my young self, embarking on my Ph.D. at the age of 20. Did I pick an interesting problem to study? Yes. Will it still be interesting in 10--20 years time? Emphatically yes. The past 30 years have given us all the tools we need to take the studies forward. We are now poised, as cell biologists, to make major contributions to human health in the next 50 years.
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